K

Kilitch Drugs (India) Ltd
NSE:KILITCH

Watchlist Manager
Kilitch Drugs (India) Ltd
NSE:KILITCH
Watchlist
Price: 310.05 INR 1.29% Market Closed
Market Cap: 5B INR
Have any thoughts about
Kilitch Drugs (India) Ltd?
Write Note

Net Margin
Kilitch Drugs (India) Ltd

8.3%
Current
8%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
8.3%
=
Net Income
125.8m
/
Revenue
1.5B

Net Margin Across Competitors

Country IN
Market Cap 5B INR
Net Margin
8%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 710.5B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 373.5B USD
Net Margin
17%
Country US
Market Cap 251.1B USD
Net Margin
19%
Country CH
Market Cap 202.7B CHF
Net Margin
20%
Country CH
Market Cap 183.3B CHF
Net Margin
35%
Country UK
Market Cap 162.4B GBP
Net Margin
13%
Country IE
Market Cap 146B USD
Net Margin
-126%
No Stocks Found

Kilitch Drugs (India) Ltd
Glance View

Market Cap
5B INR
Industry
Pharmaceuticals

Kilitch Drugs (India) Ltd. engages in the manufacture and sale of pharmaceuticals, medicinal chemical, and botanical products. The company is headquartered in Mumbai, Maharashtra. The company is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s products include parenteral solutions, effervescent, nutritional products, and medical device. Its products categories include urinary alkalizer, cephalosporins products, gastroenterology, non steroidal anti-inflammatory drugs (NSAIDs), anticonvulsant/antiepileptic, adrenergic agonist, neurotonic, muscle relaxant/stimulant, aminoglycosides, anti-infective, anti-inflammatory, anti-malarials, anti-hypertensive, anaesthetic, uterine stimulants. Its parenteral solutions include neurotonic, veterinary products, metered nasal drops, vaccines, oncology, and ophthalmic products. Its effervescent products include Roipar, Duregra, And Roivit. The firm offers nutritional products, such as Celtine. The firm also offers medical devices, such as C-Seal.

KILITCH Intrinsic Value
285 INR
Overvaluation 8%
Intrinsic Value
Price
K

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
8.3%
=
Net Income
125.8m
/
Revenue
1.5B
What is the Net Margin of Kilitch Drugs (India) Ltd?

Based on Kilitch Drugs (India) Ltd's most recent financial statements, the company has Net Margin of 8.3%.